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Background: Dysfunction of the meibomian gland (MG) is among the most frequent causes of 
ophthalmological symptoms. The inflammation seen in meibomian gland dysfunction (MGD) 
is part of its pathogenesis, and evidence of the antioxidant-inflammatory properties of omega-3 
fatty acids suggests this to be an appropriate treatment for MGD.
Objective: We aimed to assess the effectiveness of omega-3 fatty acids versus placebo, in 
improving the symptoms and signs of MGD.
Methods: We conducted a randomized and double-mask trial of 3 months duration. We enrolled 
61 patients who presented with symptomatic MGD and no tear instability (defined as tear 
breakup time [TBUT] ,10 seconds). Participants were randomly assigned to two homogeneous 
subgroups. For patients in group A, the study treatment included cleaning the lid margins with 
neutral baby shampoo and use of artificial tears without preservatives, plus a placebo oral agent. 
For patients in group B, the study treatment included cleaning the lid margins with neutral baby 
shampoo and use of artificial tears without preservatives, plus oral supplementation with omega-3 
fatty acids. We performed the following tests: (1) TBUT; (2) Schirmer I test; (3) Ocular Surface 
Disease Index© (OSDI©; Allergan, Inc., Irvine, CA, USA); (4) MG expression; (5) evaluation 
of lid margin inflammation; and (6) interpalpebral and corneal dye staining.
Results: After 3 months of evaluation, the mean OSDI, TBUT, lid margin inflammation, and MG 
expression presented improvement from the baseline values, in group B (P , 0.01, P , 0.001, 
P , 0.0001, P , 0.0001, respectively). The Schirmer test results were also improved and sta-
tistically significant (P , 0.01).
Conclusion: Oral omega-3 fatty acids, 1.5 grams per day, may be beneficial in the treatment 
of MGD, mainly by improving tear stability.
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Introduction
Dysfunction of meibomian gland (MG) is included among the most frequent causes 
of ophthalmological disorders and is the principal cause of dry eye.1 As stated by 
the report2 from an international workshop on MG dysfunction (MGD), the main 
mechanisms responsible for the development of obstructive MGD are increased 
meibum viscosity and hyperkeratinization of the ductal epithelium. These processes 
are influenced by aging, use of contact lenses, topical medications, and hormonal 
variations. We can also add acinar atrophy and inflammation as common causes of 
MGD. MGD should be considered as one of the most frequent causes of lipid tear 
deficiency, responsible for tear instability and for the appreciable shortening of the 
tear breakup time TBUT.3,4
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The regular treatments for MGD comprise: cleansing of 
the lid, use of artificial tears, topical application of corticoster-
oids and erythromycin, and oral tetracycline/doxycycline.3–5 
These measures are usually inefficient and do not effectively 
target the core mechanism of MGD. Thus, the degenerative 
processes (eg, hyperkeratosis) of the MG have an important 
influence in the MGD pathogenesis.
Tear cytokines also play an important role in chronic 
inflammation in MGD. When inflammatory cytokine levels in 
the tears of MGD patients and controls were compared, 
interleukin (IL)-1β, IL-7, IL-12, IL-17, and macrophage 
inflammatory protein-1β levels were found to be higher in 
the MGD patients.6,7 Furthermore, IL-6, IL-8, IL-12, tumor 
necrosis factor (TNF)-α levels, and interferon-γ were higher 
in patients with dysfunctional tear syndrome with MGD, 
compared with the control group.8
Essential fatty acid supplementation has been shown 
to have an anti-inflammatory effect on dry eye symptoms.9 
Fish oil is a source of long-chain omega-3 polyunsaturated 
fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic 
acid. The omega-3 fatty acid EPA and the omega-6 fatty acid 
arachidonic acid (AA) act competitively as a substrate for both 
the enzyme cyclooxygenase and the enzyme 5-lipoxygenase. 
The anti-inflammatory action is believed to result from the 
synthesis of prostaglandin E3 and leukotriene B5 (LTB5) 
from EPA that inhibits the conversion of AA to the potentially 
harmful inflammatory mediator’s prostaglandin E2 and 
leukotriene B4.10
In the present study, we evaluated the effectiveness of 
oral supplementation with a combined formulation of anti-
oxidants and omega-3 in improving the signs and symptoms 
of diagnosed MGD, compared with placebo.
Materials and methods
This randomized, double-masked study/trial was performed 
with the approval of the ethics committee and the institutional 
review boards of the University Hospital Jiménez Díaz 
Foundation (Madrid, Spain). All tenets of the Declaration 
of Helsinki for the protection of human subjects in medical 
research were strictly observed.
Study design
A total of 61 subjects of both sexes, aged 23–85 years, were 
enrolled during ophthalmologic appointments at the study 
center, the University Hospital Jiménez Díaz Foundation 
in Madrid, Spain, between March 2012 and December 
2012, according to the main inclusion/exclusion criteria 
listed in Table 1.
Prior to the baseline visit, subjects were required to 
discontinue use of nutritional supplements and related treat-
ments, such as antibiotics, nonsteroidal anti-inflammatory 
drugs, corticosteroids, and tears with vitamins, for at least 
15 days. Participants were asked to strictly follow the recom-
mendations of the ophthalmologists throughout the duration 
of the study. Ocular lubricants without nutritional agents were 
not restricted. Patients with obvious infection were excluded 
from the present study. Patients diagnosed with MGD were 
enrolled, according to criteria identified at a 2011 interna-
tional workshop on MGD.11
To classify our study participants, we performed sys-
tematic ophthalmologic examinations and administered a 
questionnaire with objective and subjective criteria. At the 
baseline visit (month 0), patients were checked for signs 
and symptoms of MGD, and we applied the inclusion and 
exclusion criteria of the trial protocol. The assessed base-
line parameters were: (1) TBUT; (2) tear quantification, 
(Schirmer I test);3,4 (3) Ocular Surface Disease Index© (OSDI) 
(American Optometric Association, St Louis, MO, USA); 
(4) MG expression and secretion; (5) lid margin inflammation 
evaluation; (6) interpalpebral and corneal dye staining; and 
(7) fluorescein stain of the cornea. Furthermore, patients used 
a daily tear complement without preservatives, which was 
measured. All participants were required, on a daily basis, to 
apply a warm compress for 5 minutes and to scrub the eye 
with diluted baby shampoo.
All participants additionally took an oral agent (one cap-
sule taken with each of the three main meals per day). The 
participants were randomly assigned to group A or group B. 
Group A patients received a placebo oral supplement: 500 mg 
capsules incorporating sunflower oil with no other compo-
nents or excipients apart from gelatin (bovine) and titanium 
oxide colorants, iron oxide, and hydroxides. Participants 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Aged 18–85 years Aged ,23 years or .85 years
Diagnosed with MgD Atopy, allergic disorders
Able to participate in  
the study
Contact lenses
Informed consent Ophthalmic laser treatment (less than 3 months)
Systemic diseases and general treatments
Pregnancy
Systemic disease associated with dry eye
Blepharitis without MgD diagnosis
Ocular disorders and eye drops other than 
artificial tears
Unable to participate in the study
Abbreviation: MgD, meibomian gland dysfunction.
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in group B received the study oral supplement formulation 
(Brudysec 1.5 g; Brudy Lab SL, Barcelona, Spain) reported in 
Table 2. The supplement for group B was based on omega-3, 
vitamins, glutathione, amino acids, and oligoelements in 
a combined nutraceutical formulation and contained (per 
capsule) docosahexaenoic acid (350 mg), eicosapentaenoic 
acid (42.5 mg), docosapentaenoic acid (30 mg), vitamin A 
(133.3 µg), vitamin C (26.7 mg), vitamin E (4 mg), tyrosine 
(10.8 mg), cysteine (5.83 mg), glutathione (2 mg), zinc 
(1.6 mg), copper (0.16 mg), manganese (0.33 mg), and 
selenium (9.17 µg).
The objective factors were reassessed at follow-up visits 
1, 2, and 3 months after the assigned treatments began. The 
objective factors were evaluated by one investigator (AO) 
to reduce interobserver variability. We assumed a self-
administered medical therapy has only 50% adherence, so 
at each visit, the patients were required to deliver the empty 
boxes of medication received, in order to improve compli-
ance as well as to ensure the validity of the final data of the 
study. Subjects were followed up monthly, for 3 months 
after the initial visit.
Patient management
Personal interviews were conducted with all participants to 
obtain their personal and familial backgrounds and character-
istics of their disease, mainly symptoms of MGD. The OSDI 
questionnaire assessed the frequency of dry eye symptoms 
and problems with the ocular surface.12 The OSDI assessed 
the participants’ condition as normal, mild, moderate, or 
severe.
All participants underwent a systematic ophthalmologic 
examination to determine best corrected visual acuity in each 
eye. The objective signs were evaluated by means of a slit-
lamp IS-600II Topcon (Topcon Corporation, Tokyo, Japan) 
examination (lid margin inflammation and MG expression), 
staining of the conjunctiva and cornea with fluorescein (Oxford 
Test),13 measurement of TBUT,3,4 and the quantification of 
the tear assessed by Schirmer I test. Lid margin inflammation 
severity was scored: 0, no injection; 1, injection (presence of 
conjunctival vessels congestion and/or hyperemia) (Table 3).
MGD was defined as abnormal discharge and/or anomalous 
expression when a finger was placed on both palpebral lids: 
clear fluid, cloudy fluid, cloudy particulate fluid, or inspissated 
and toothpaste-like (Table 3).1 The primary ophthalmologic 
outcome measures for effectiveness of the oral nutraceutical 
formulation were fluorescein staining and TBUT; the second-
ary measures were Schirmer I test and dry eye symptoms.12
TBUT was measured by instillation of one drop of 2% 
fluorescein. The time until disappearance of the dye was 
recorded, and the average of three trials was calculated. On 
the other hand, we used the Oxford Test in order to evaluate 
the corneal fluorescein. Also, the Schirmer I test (quantifi-
cation of the tear) was applied during a 5 minute interval, 
Table 2 Composition of Brudysec 1.5 g (Brudy Lab SL, Barcelona, 
Spain), per capsule
Nutrient Amount
DhA 350 mg
EPA 42.5 mg
Vitamin A 133.3 µg
Vitamin C 26.7 mg
Vitamin E 4 mg
Tyrosine 10.8 mg
Cysteine 5.83 mg
glutathione 2 mg
Zinc 1.6 mg
Copper 0.16 mg
Manganese 0.33 mg
Selenium 9.17 µg
DPA 30 mg
Abbreviations: DhA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, 
eicosapentaenoic acid.
Table 3 Baseline patient characteristics
Characteristic Placebo  
(group A;  
n = 31)
Omega-3 
(group B; 
n = 33)
Sex
 Male, n (%) 9 (29.03) 9 (27.2)
 Female, n (%) 22 (70.97) 24 (72.8)
Age in years, mean 54 58
Signs
Lid margin inflammation severity, n (%)
 No injection 9 (29.03) 10 (30.3)
 Injection 22 (70.97) 23 (69.7)
Meibomian gland secretion, n (%)
 Clear fluid 1 (3.22) 4 (12.12)
 Cloudy fluid 21 (67.74) 20 (60.60)
 Cloudy particulate fluid 6 (19.35) 8 (24.24)
 Inspissated, like toothpaste 3 (9.68) 1 (3.03)
 No secretion 0 0
Mean TBUT (SD), s 6.45 (2.57) 6.94 (2.75)
Mean Schirmer I (SD), mm 16.61 (7.57) 18.94 (7.47)
Cornea staining data. Oxford test, n (%)
 grade 0 23 (74.2) 22 (66.7)
 grade I 5 (16.1) 11 (33.3)
 grade II to IV 3 (9.7) 0 (0)
Symptoms
OSDI©
 Normal 2 0
 Mild 7 4
 Moderate 12 17
 Severe 10 12
Abbreviations: OSDI©, Ocular Surface Disease Index; SD, standard deviation; 
TBUT, tear breakup time; s, seconds.
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without anesthesia. We evaluated the safety outcomes by 
means of ophthalmological explorations, and any adverse 
events that occurred, during the whole of the research.
Statistical analysis
We analyzed the outcomes of patients’ right eyes. The most 
significant results came from the TBUT test. Statistics are 
reported as mean values and standard deviations. We used 
dependent-samples Student’s t (TBUT and Schirmer), 
McNemar (inflammation of the lids and expression of 
the MG), and Wilcoxon tests (OSDI and Oxford) for 
intragroup and intergroup comparisons. Both intragroup 
and intergroup comparisons were made with an intention-
to-treat analysis. P-values (two-sided) less than 0.05 were 
considered statistically significant. Statistical analyses 
were performed with the Statistical Package for the Social 
Sciences, Version 11.0 software (SPSS, Inc., Chicago, 
IL, USA).
Results
Patient demographics
We recruited 64 patients in the research; 31 were assigned 
to group A, and 33 were assigned to group B. Three patients 
(from group B) were withdrawn from the study: two (3.12%) 
because of drug intolerance, and one (1.56%) did not pursue 
the treatment.
Sixty-one patients completed the study: 31 (50.82%) in 
group A and 30 (49.18%) in group B. The mean age of the 
group B patients was 58 years and was 54 years for group A. 
Most of the patients involved in the study were women, but 
we did not observe significant differences in the sex distribu-
tion for both groups.
Additionally, we did not observe significant intergroup 
differences in baseline signs and symptoms. Table 3 sum-
marizes the baseline data, including demography, and the 
signs and symptoms. Throughout the randomized study, 
the investigators and patients were blinded to the treatment 
assignments.
Treatment responses
At baseline, the mean TBUT was 6.45 (2.57) seconds 
and 6.94 (2.75) seconds for groups A and B, respectively 
(Table 3). At each monitoring, the mean TBUT for group B 
was greater than the baseline and the group A values. The 
TBUT at the final follow-up visit was 8.03 (2.86) seconds and 
12.63 (1.75) seconds in group A and in group B, respectively 
(P , 0.01) (Figure 1).
In the control group (group A), the TBUT did not change 
significantly from baseline. However in group B, lid inflam-
mation was decreased significantly compared with baseline, 
at each follow-up (P , 0.0001).
In group B, the MG expressibility was significantly 
greater than baseline, at 1 month (P = 0.01) and at 3 months 
(P , 0.0001); group A did not present a change in 
expressibility.
In both groups, cornea staining data presented no signifi-
cant differences from baseline, although the group B results 
were lower at each monitored visit.
The mean tear quantification was assessed by the Schirmer 
I test, without anesthesia. At baseline, this was 16.61 (7.57) 
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Figure 1 Changes in mean tear breakup time, from baseline to month 3, in subjects assigned to omega-3 or placebo.
Note: The differences between month 3 and baseline values were statistically significant (P , 0.001).
Abbreviation: TBUT, tear breakup time; s, seconds.
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mm in group A and 18.94 (7.47) mm in group B. The tear 
quantification results at 3 months were not significantly dif-
ferent from baseline in either group.
The dysfunctions of the tear were evaluated using the 
OSDI test. Both groups exhibited a decrease in tear dysfunc-
tion symptoms in group B, the decrease was observed at 
1 month and 3 months (P = 0.01 and P = 0.09, respectively), 
and in group A, this was also observed at both of the follow-
up visits (P = 0.09 and P = 0.003, respectively).
Discussion
The main cause of MGD is hyperkeratinization and its 
related pathogenesis (for example, ductal dilatation and 
acinar atrophy). Other pathologies, such as atopy, pemphi-
goid, acne rosacea, and seborrhea are related to MGD and 
may result in a chronic inflammation of the ocular surface.14 
Thus, all these circumstances may also lead to dry eye, the 
alteration of the tear, and irritation of the eye shown by 
MGD patients.
Furthermore, other factors, such as: IL-6, IL-8, IL-12, 
TNF-α levels, and interferon-γ may be increased in MGD;8,15 
the latter may explain the irritation and lid inflammation 
symptoms noticed in patients with this disorder. Based on 
these effects, inflammatory properties may be targeted in the 
treatment of MGD.
The anti-inflammatory power of essential polyunsatu-
rated fatty acids used in treatment of the ocular surface may 
be compared with corticosteroids, as they act as the same 
mediator, through nuclear factor kappa B (NF-κB) signal 
transduction, of the inflammation cascade.16 The inflam-
mation at the lid margin presented improvement from the 
baseline in group B (who took the omega-3 fatty acids 
supplement), and consequently, this study suggests that 
omega-3 fatty acids may improve tear film stability, decrease 
the inflammation of lid margins, and recover the homeostasis 
of ocular surface in patients with MGD.
Wojtowicz et al17 did not find statistically significant dif-
ferences between omega-3 and placebo in the treatment of 
dry eye; nevertheless, we did find statistically significant 
differences in our assessment of the TBUT test after treat-
ment with omega-3 for MGD. This study is a starting point 
for further research into the benefit of omega-3 fatty acids 
for inflammatory disease of the ocular surface, and other 
studies should aim to quantify the beneficial effect of 
omega-3 fatty acids in MGD with evaporative dry eye, for 
example, by incrementally increasing the dose of omega-3 
fatty acids and assessing the anti-inflammatory effect. We 
should also consider other research improvements, for 
eg, balancing the ratio of males to females in the study 
population.
A strength of this research is that it was randomized and 
double-masked, which may have minimized any partiality. 
The main outcome measure of efficacy was tear film stability, 
and greater differences might have been observed in a larger 
patient sample. A larger, controlled, and multicenter study 
may be required in order to confirm whether this improvement 
in tear stability is applicable to clinical practice.
Adverse events
No serious adverse events arose during the research. Of 
64 patients, two patients (3.12%) in the preliminary-stage 
(intention-to-treat) analysis group reported digestive upset 
with omega-3 treatment. These symptoms arose within the 
first month of treatment, and the patients recovered imme-
diately after stopping the medication.
Conclusion
To conclude, this research established that omega-3 fatty 
acids, 1.5 g, can increase TBUT in subjects with MGD. Thus, 
when conventional treatment (artificial tears) has proven 
unsatisfactory for patients with MGD, omega-3 fatty acids, 
1.5 g, may be an effective adjunctive treatment.
Acknowledgments
The food supplements used this trial were provided by Brudy 
Lab SL, Barcelona, Spain.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for 
description, diagnosis, classification, and grading. Ocul Surf. 2003;1(3): 
107–126.
2. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international 
workshop on meibomian gland dysfunction: report of the subcommittee 
on anatomy, physiology, and pathophysiology of the meibomian gland. 
Invest Ophthalmol Vis Sci. 2011;52(4):1938–1978.
3. Mathers WD. Meibomian gland disease. In: Pflugfelder SC, 
Beuerman RW, Stern ME, editors. Dry Eye and Ocular Surface 
Disorders. New York, NY: Marcel Dekker Inc; 2004:247–267.
4. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol. 
1996;40(5):343–367.
5. Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease. Classification 
and grading of lid changes. Eye (Lond). 1991;5(Pt 4):395–411.
6. Kim JT, Lee SH, Chun YS, Kim JC. Tear cytokines and chemokines in 
patients with Demodex blepharitis. Cytokine. 2011;53(1):94–99.
7. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and 
anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva 
of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42(10): 
2283–2292.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1137
Omega-3 fatty acids supplementation in meibomian gland dysfunction
Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treat-
ments intended to prevent or delay the onset of maladaptive correlates 
of aging in human beings. This journal is indexed on PubMed Central, 
MedLine, the American Chemical Society’s ‘Chemical Abstracts 
Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Clinical Interventions in Aging 2013:8
 8. Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC. 
Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 
2009;147(2):198–205. e1.
 9. Brignole-Baudouin F, Baudouin C, Aragona P, et al. A multicentre, 
double-masked, randomized, controlled trial assessing the effect of 
oral supplementation of omega-3 and omega-6 fatty acids on a con-
junctival inflammatory marker in dry eye patients. Acta Ophthalmol. 
2011;89(7):e591–e597.
 10. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids 
and inflammatory mediator production. Am J Clin Nutr. 2000;71(Suppl 1): 
343S–348S.
 11. Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on 
meibomian gland dysfunction: report of the diagnosis subcommittee. 
Invest Ophthalmol Vis Sci. 2011;52(4):2006–2049.
 12. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. 
Reliability and validity of the Ocular Surface Disease Index. Arch 
Ophthalmol. 2000;118(5):615–621.
 13. Methodologies to diagnose and monitor dry eye disease: report of the 
Diagnostic Methodology Subcommittee of the International Dry Eye 
Workshop. Ocular Surface. 2007 Apr;5(2):108–152. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/17508118. Accessed July 1, 2013. 
 14. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on 
meibomian gland dysfunction: executive summary. Invest Ophthalmol 
Vis Sci. 2011;52(4):1922–1929.
 15. Enríquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine 
and chemokine analysis and clinical correlations in evaporative-type 
dry eye disease. Mol Vis. 2010;16:862–873.
 16. Erdinest N, Shmueli O, Grossman Y, Ovadia H, Solomon A. 
 Anti-inflammatory effects of alpha linolenic acid on human corneal 
epithelial cells. Invest Ophthalmol Vis Sci. 2012;53(8):4396–4406.
 17. Wojtowicz JC, Butovich I, Uchiyama E, Aronowicz J, Agee S, McCul-
ley JP. Pilot, prospective, randomized, double-masked, placebo-con-
trolled clinical trial of an omega-3 supplement for dry eye. Cornea. 
2011;30(3):308–314.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1138
Oleñik et al
